NEKTAR THERAPEUTICS - 8-K Filing
Nektar Therapeutics enters quiet period ahead of Phase 2b REZOLVE-AA study data announcement (Items: 7.01 Regulation FD, 9.01 Financial Statements and Exhibits)
Tickers: $NKTR
Nektar Therapeutics enters quiet period ahead of Phase 2b REZOLVE-AA study data announcement (Items: 7.01 Regulation FD, 9.01 Financial Statements and Exhibits)
Tickers: $NKTR